BSF Enterprise PLC (GB:BSFA)
LSE:BSFA
Want to see GB:BSFA full AI Analyst Report?
Top Page
BSF Enterprise PLC
(LSE:BSFA)
Select Model
Select Model
Rating:42Neutral
Price Target:
0.94 p
▼(-50.79% Downside)
Action:Reiterated
Date:06/13/26
The score is primarily weighed down by weak financial performance (persistent losses and negative cash flow) and bearish technical positioning (trading below key moving averages with weak momentum). Valuation provides limited support because the company is loss-making and no dividend yield is available.
Positive Factors
Proprietary IP
BSF's patented tissue‑engineering and cellular agriculture technologies provide durable barriers to entry and differentiation. Ownership of IP supports licensing, partnerships and recurring B2B revenue streams, enabling long‑term monetisation beyond one‑off product sales.
Negative Factors
Persistent Unprofitability
Gross profit is consistently negative and net losses are large relative to revenue, indicating core unit economics are not yet viable. Continued unprofitability erodes equity and requires sustained external funding, posing a durable profitability risk until costs or pricing materially change.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary IP
BSF's patented tissue‑engineering and cellular agriculture technologies provide durable barriers to entry and differentiation. Ownership of IP supports licensing, partnerships and recurring B2B revenue streams, enabling long‑term monetisation beyond one‑off product sales.
Read all positive factors
BSF Enterprise PLC (BSFA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£2.18M
Dividend YieldN/A
Average Volume (3M)374.14K
Price to Earnings (P/E)―
Beta (1Y)3.89
Revenue Growth-8.61%
EPS Growth42.59%
CountryUK
Employees15
SectorHealthcare
Sector Strength45
IndustryAsset Management
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding193,749,440
10 Day Avg. Volume343,597
30 Day Avg. Volume374,142
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.46
Price to Sales (P/S)75.11
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BSF Enterprise PLC Business Overview & Revenue Model
Company Description
Incorporated in 2018 and headquartered in London, United Kingdom, BSF Enterprise Plc currently holds no significant active operations. Its strategic focus is on acquiring businesses or companies primarily within the marketing and technology sectors....
How the Company Makes Money
BSF Enterprise PLC generates revenue by leveraging its patented tissue-engineering and cellular agriculture technologies. Its primary revenue streams include the licensing of its technology to food and biotechnology companies, sales of cultured me...
BSF Enterprise PLC Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 52.84K | 57.82K | 12.94K | 0.00 | 0.00 |
| Gross Profit | -127.47K | -26.64K | -86.55K | -160.50K | 0.00 |
| EBITDA | -1.10M | -1.68M | -1.46M | -905.76K | -58.22K |
| Net Income | -1.11M | -1.67M | -1.50M | -930.04K | -58.43K |
Balance Sheet | |||||
| Total Assets | 3.01M | 3.50M | 5.26M | 4.03M | 401.45K |
| Cash, Cash Equivalents and Short-Term Investments | 149.02K | 637.66K | 2.32M | 1.06M | 359.87K |
| Total Debt | 0.00 | 78.05K | 156.93K | 231.88K | 0.00 |
| Total Liabilities | 289.02K | 305.07K | 401.63K | 449.47K | 36.63K |
| Stockholders Equity | 2.72M | 3.19M | 4.86M | 3.58M | 364.82K |
Cash Flow | |||||
| Free Cash Flow | -1.02M | -1.60M | -1.44M | -677.86K | -85.19K |
| Operating Cash Flow | -1.01M | -1.59M | -1.38M | -667.24K | -85.19K |
| Investing Cash Flow | -9.92K | -12.02K | -64.85K | 1.75K | 0.00 |
| Financing Cash Flow | 529.69K | -78.88K | 2.70M | 1.37M | 0.00 |
BSF Enterprise PLC Technical Analysis
Negative
1.90
Price Trends
1.76
Negative
1.61
Negative
2.06
Negative
Market Momentum
-0.21
Positive
37.81
Neutral
16.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BSFA, the sentiment is Negative. The current price of 1.9 is above the 20-day moving average (MA) of 1.81, above the 50-day MA of 1.76, and below the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 37.81 is Neutral, neither overbought nor oversold. The STOCH value of 16.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:BSFA.
BSF Enterprise PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £4.61M | 5.15 | -12.33% | ― | -106.88% | -66.67% | |
48 Neutral | £2.94M | -2.19 | -37.63% | ― | -100.66% | 84.15% | |
48 Neutral | £2.90M | ― | 37.98% | ― | ― | ― | |
43 Neutral | £3.33M | -4.42 | -140.34% | ― | ― | 89.03% | |
42 Neutral | £2.18M | -1.12 | -46.41% | ― | -8.61% | 42.59% |
* Healthcare Sector Average
GB:BSFA
BSF Enterprise PLC
1.13
-1.13
-50.00%
GB:BLU
Blue Star Capital
7.00
-17.00
-70.83%
GB:TRUE
Braveheart Investment
3.75
1.40
59.57%
GB:MFAI
Pires Investments
0.53
-0.48
-47.50%
GB:PRIM
Primorus Investments
3.70
-0.30
-7.50%
GB:CGO
Contango Holdings Plc
0.45
-0.50
-52.63%
BSF Enterprise PLC Corporate Events
Business Operations and StrategyPrivate Placements and Financing
BSF Uses Paris T‑Rex Handbag Auction to Validate Bio-Materials Platform and Attract Tier‑1 Partners
Positive
Jun 16, 2026
BSF Enterprise has framed the Paris auction of its T-Rex Leather handbag as a successful technical stress-test of its scaffold-free Advanced Tissue Engineering Platform, rather than a consumer luxury push. Although bidding stopped at €150,00...
Business Operations and StrategyProduct-Related Announcements
BSF’s T-Rex Leather Handbag Unsold in Paris as Corporate Interest in Bio-Leather Grows
Positive
Jun 12, 2026
BSF Enterprise PLC reported that the first-ever product made from its T-Rex Leather™, a museum-grade luxury handbag created with avant-garde designer Enfin Levé, drew strong global interest at a Paris auction but did not meet the reserv...
Business Operations and StrategyPrivate Placements and Financing
BSF Enterprise Secures £1m Convertible Funding to Advance Tissue-Engineered Products
Positive
Jun 11, 2026
BSF Enterprise PLC has secured a £1 million interest-free convertible loan note from Indigo Capital LP to bolster working capital and fund ongoing commercial activities and product development. The 12-month, zero-coupon facility can be conver...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingShareholder Meetings
BSF Enterprise Wins Shareholder Backing for Share Issue and LSE Admission
Positive
Jun 8, 2026
BSF Enterprise PLC reported that shareholders approved all resolutions at its latest general meeting, granting directors authority to allot shares for both specific and general purposes and to disapply pre-emption rights. The strong majority backi...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
BSF Enterprise Raises £500,000 in Conditional Share Placing to Fund Growth Plans
Positive
Jun 3, 2026
BSF Enterprise PLC has conditionally raised £500,000 through a placing of 25,000,000 new ordinary shares at 2p each, with proceeds earmarked to support its strategic business and growth plans during 2026. The company will also issue 1,500,000...
Business Operations and StrategyProduct-Related Announcements
BSF Enterprise Showcases T-Rex Leather Breakthrough in New Technical White Paper
Positive
Jun 2, 2026
BSF Enterprise’s Lab-Grown Leather unit has released a technical white paper on its proprietary T-Rex Leather line, detailing the engineering biology behind recreating T. rex collagen, its structural advantages, and its potential in the luxu...
Business Operations and StrategyProduct-Related Announcements
BSF’s €500,000 T-rex Handbag Auction Spurs Tier-1 Brand Interest
Positive
May 28, 2026
BSF Enterprise’s Lab-Grown Leather unit has secured a prominent listing for its flagship bio-engineered T-rex leather handbag in the auction catalogue of Paris auction house Hôtel Drouot. Following a rigorous appraisal, the one-of-a-kin...
Business Operations and StrategyProduct-Related Announcements
BSF Enterprise Marks 2026 as Pivotal Year with Commercial Push and Spin-Out Plans
Positive
May 26, 2026
BSF Enterprise PLC has outlined a major strategic shift from pure RD to commercialisation across its three subsidiaries, highlighting 2026 as a pivotal year. The company emphasises a multi-asset model designed to spread risk and pursue anti-diluti...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
BSF Enterprise Seeks Expanded Share Issuance Powers Ahead of June General Meeting
Positive
May 22, 2026
BSF Enterprise PLC, a global pioneer in lab-grown tissues and sustainable biotechnology, has sent a circular and notice of general meeting to shareholders ahead of a vote on expanding its capital-raising flexibility. The company, listed in London ...
Business Operations and StrategyProduct-Related Announcements
BSF to Auction World’s First T-Rex Leather Handbag in Paris
Positive
May 5, 2026
BSF Enterprise PLC’s Lab-Grown Leather subsidiary has appointed Paris auction house Giquello SAS to sell the world’s first handbag made from its proprietary T-Rex Leather, a material engineered from reconstructed dinosaur collagen and ...
Delistings and Listing ChangesRegulatory Filings and Compliance
BSF Enterprise Confirms Share Admissions and Corrects Broker Warrants Disclosure
Neutral
Apr 17, 2026
BSF Enterprise PLC, a leading innovator in tissue-engineered materials, focuses on commercialising lab-grown leather, cultivated meat, and corneal repair products using its proprietary scaffold-free ATEP platform. The company aims to serve global ...
Business Operations and StrategyProduct-Related Announcements
BSF Enterprise Showcases World’s First Handbag Made from Cultivated T-Rex Leather
Positive
Apr 7, 2026
BSF Enterprise’s Lab-Grown Leather subsidiary has unveiled what it calls the world’s first handbag made from cultivated T-Rex Leather, a biomaterial engineered from reconstructed dinosaur collagen, now on display at the Art Zoo Museum ...
Business Operations and StrategyPrivate Placements and Financing
BSF Enterprise Raises £385,000 in Share Placing and Appoints New Financial Adviser
Positive
Apr 2, 2026
BSF Enterprise PLC has raised £385,000 through a placing of 38,500,000 new ordinary shares at 1p each to a single strategic investor, arranged within existing headroom and accompanied by one-for-one investor warrants exercisable at 1.5p over ...
Business Operations and StrategyProduct-Related Announcements
BSF Enterprise Debuts World’s First Lab-Grown T-Rex Leather Handbag
Positive
Apr 2, 2026
BSF Enterprise PLC has unveiled what it describes as the world’s first product made from lab-grown T-Rex Leather, a one-of-a-kind luxury handbag created with avant-garde label Enfin Levé and showcased at Amsterdam’s Art Zoo Museum...
Business Operations and Strategy
BSF Enterprise seals five-year City-Mix supply deal with South Korea’s SeaWith
Positive
Mar 19, 2026
BSF Enterprise’s subsidiary 3D Bio-Tissues has signed a five-year commercial supply agreement with South Korean cultivated meat specialist SeaWith to provide its proprietary City-Mix macromolecular crowder. The deal, estimated to be worth ab...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.